Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The single nucleotide variant n.60G > C in the microRNA-146a associated with susceptibility to drug-resistant epilepsy

Full text
Boschiero, Matheus Negri [1] ; Camporeze, Bruno [1] ; dos Santos, Jessica Silva [1] ; da Costa, Leandro Borsari [1] ; Bonafe, Gabriel Alves [1] ; Queiroz, Luciano de Souza [2] ; Van Roost, Dirk [3] ; Lima Marson, Fernando Augusto [1] ; Pires de Aguiar, Paulo Henrique [1, 4, 5] ; Ortega, Manoela Marques [1]
Total Authors: 10
[1] Sao Francisco Univ, Lab Cell & Mol Tumor Biol & Bioact Cpds, Med Sch USF, Braganca Paulista, SP - Brazil
[2] Univ Estadual Campinas, Dept Pathol, Unicamp, Campinas, SP - Brazil
[3] Ghent Univ Hosp, Dept Neurosurg, Ghent - Belgium
[4] ABC Med Sch, Santo Andre, SP - Brazil
[5] State Civil Servant Hosp IAMSPE, Dept Neurosurg, Postgrad Program, Sao Paulo, SP - Brazil
Total Affiliations: 5
Document type: Journal article
Source: Epilepsy Research; v. 162, MAY 2020.
Web of Science Citations: 0

Objective: The aim of this study was to evaluate single nucleotide variants (SNVs) n.-411A > G (rs57095329) and n.60 G > C (rs2910164) in microRNA (miR)-146a, related to suppressing of TRAF6 with risk for epilepsy, as well as miR-146a and TRAF6 levels. Methods: DNAs were extracted from epileptogenic tissues and blood leukocytes from drug-resistant epilepsy patients and healthy-individuals, respectively. Genotypes were identified by real-time PCR. Hardy-Weinberg equilibrium (HWE) and Fisher or X-2 tests evaluated the difference between groups. The disease risk was assessed by odds ratio (OR) with 95 % confidence interval (95 %CI). The prognostic impact on probability seizure-free survival (PSF) was evaluated by Kaplan-Meier and log-rank tests. Results: For rs57095329 both control and patient samples were not in HWE (p < 0.05) and the genotypes prevalence was similar in patients and controls (p > 0.05). For rs2910164, control samples were in HWE (p = 0.61), contrasting with patients (p = 0.03), and similar frequencies of wild-type homozygous (GG) (43.4 % vs. 34.4 %, p = 0.2) and variant (CC) genotypes (8.0 % vs. 6.6 %, p = 0.6) were observed in patients and controls, respectively. However, increased frequency of heterozygous (GC) was observed in patients compared to controls (59.0 % vs. 42.7 %, p = 0.04) with 1.98 (95 %CI = 1.09-3.57) risk for epilepsy. The miR-146a expression level in the epileptogenic tissues was lower in the GC (p = 0.02) and CC (p = 0.09) compared to GG genotype. TRAF6 expression level was higher in CC than in GG genotype (p = 0.09). Interestingly, there was an increased frequency of patients harboring GC genotype and less time until surgery compared to patients harboring GG or CC (36.06 % vs. 11.5 %, p = 0.01), confirmed by PSF ( p = 0.04). Conclusions: The GC genotype for SNV rs2910164 appears associated with susceptibility to drug-resistant epilepsy due to the decreased MIR146a expression, favoring NF-kB pathway through TRAF6. (AU)

FAPESP's process: 18/12057-0 - Characterization of a single nucleotide polymorphism in the microRNA-146a and epilepsy susceptibility
Grantee:Bruno Camporeze
Support type: Scholarships in Brazil - Scientific Initiation